Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prodomain mutations at the subtilisin interface: correlation of binding energy and the rate of catalyzed folding.

Biochemistry·1995
Same author

Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.

Journal of medicinal chemistry·1995
Same author

Thermodynamic parameters for the helix-coil transition of oligopeptides: molecular dynamics simulation with the peptide growth method.

Proceedings of the National Academy of Sciences of the United States of America·1995
Same author

The sixty nucleotide OccR operator contains a subsite essential and sufficient for OccR binding and a second subsite required for ligand-responsive DNA bending.

Journal of molecular biology·1995
Same author

Cloning of a cDNA encoding a 190-kDa insulin receptor substrate-1-like protein of simian COS cells.

Biochemical and biophysical research communications·1995
Same author

Differences in oxidative response of subpopulations of neutrophils from healthy subjects and patients with rheumatoid arthritis.

Annals of the rheumatic diseases·1995

Related Experiment Video

Updated: Jun 17, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

[Treatment options for marginal zone lymphoma].

Q Jiang1, X Wang2, X X Xiang1

  • 1Medical Center of Hematology, the Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing 400037, China.

Zhonghua Yi Xue Za Zhi
|June 15, 2026
PubMed
Summary
This summary is machine-generated.

Marginal zone lymphoma (MZL) treatment varies widely. This review offers evidence-based guidance for initial and relapsed/refractory MZL management, promoting individualized therapeutic decisions.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Hematology
  • Oncology
  • Lymphoma Research

Background:

  • Marginal zone lymphoma (MZL) encompasses heterogeneous indolent B-cell lymphomas.
  • Current treatment guidelines and clinical practices for MZL lack standardization.
  • Diverse subtypes include mucosa-associated lymphoid tissue, nodal, and splenic MZL.

Purpose of the Study:

  • To provide evidence-based guidance for Marginal Zone Lymphoma (MZL) treatment.
  • To standardize therapeutic decision-making across different MZL subtypes.
  • To address treatment indications, initial therapies, relapsed/refractory management, and complications.

Main Methods:

  • Comprehensive literature review of MZL treatment guidelines and clinical practices.
  • Analysis of current evidence for first-line, relapsed/refractory, and maintenance therapies.
  • Synthesis of data for managing treatment-related complications in MZL.

Main Results:

  • Significant heterogeneity exists in MZL biological and clinical presentation.
  • Variability in first-line treatment options and clinical application noted.
  • A need for unified and standardized treatment pathways is identified.

Conclusions:

  • This review offers a framework for assessing treatment indications in MZL.
  • It provides guidance on initial therapies for various MZL subtypes.
  • It summarizes management strategies for relapsed/refractory MZL and complications.